Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Field Trials

26 Nov 2008 07:00

RNS Number : 9440I
Plant Health Care PLC
26 November 2008
 



26 November 2008

Plant Health Care plc ("Plant Health Care" or the "Company")

Results of the ASA Sponsored N-Hibit Seed Treatment Program

Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries and  the American Soybean Association ("ASA") are pleased to announce that the "N-Hibit® Seed Treatment Satisfaction Guarantee" program during the 2008 growing season was an unqualified success.

The results of the N-Hibit Seed Treatment program over 17 replicated trial sites, ranging from Ohio to Nebraska, produced N-Hibit-treated yields averaging 62.0 bushels/acre compared to the untreated control average of 58.6 bushels/acre. This represents a yield increase of 3.4 bushels/acre or 5.8 per cent. As a consequence, less than 3 per cent. of the acreage treated with N-Hibit resulted in requests for refunds under the Seed Treatment Satisfaction Guarantee Program. The combined effect of nematode reduction and enhanced plant growth are the primary reasons for these excellent results.

ASA President John Hoffman, a soybean producer from WaterlooIowa, commented:

"ASA partnered with PHC on the project because part of ASA's mission is to help identify new ways for ASA members to maximize soybean yield and profitability. N-Hibit's ability to reduce SCN damage and boost overall plant health is consistent with that mission, so ASA worked with PHC to make our members aware of the Satisfaction Guarantee program."

Rick Rice, Plant Health Care Director, Sales & MarketingUSA Agricultural Division stated:

"We wanted growers to share our confidence, and the Satisfaction Guarantee program assured them of a full refund of the purchase price paid for N-Hibit if they weren't fully satisfied with its performance on treated acreage. With a better than 97 percent success rate and the relationships we have developed with all the farmers involved in the program, we couldn't be more pleased." 

The active ingredient in N-Hibit is harpin protein, which stimulates the same plant growth response that occurs when a plant experiences stress. The induced response results in a healthier plant and a reduction in the number of nematodes that host on the roots. Harpin proteins do not enter the plant. They bind with the plant's external harpin protein receptors, which are present on both seed and foliage. After the proteins initiate the plant's natural self defense and growth systems, they harmlessly disintegrate. For more information about PHC, please visit www.planthealthcare.com.

  For more information contact: 

John Hoffman, ASA President +001 (319) 233 9480

John Brady, Plant Health Care plc CEO +001 603 525 3702

Evolution Securities Limited +44 (0)20 7071 4300

Tim Worlledge / Tim Redfern

Tavistock Communications Limited +44 (0)20 7920 3150

Jeremy Carey / Matt Ridsdale

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAAFSAFXPFAE
Date   Source Headline
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.